Fig. 4.

Atorvastatin treatment did not alter amphetamine (AMPH)-induced, DAT-mediated DA efflux. Cells treated with atorvastatin (Ator, 1 μM, 24 hr) were preloaded with 30 nM [³H]DA and 1 μM unlabeled DA for 30 min. Cells were quickly washed with KRH buffer and then incubated with KRH for 5 min followed by removal and replenishment with the same volume of fresh KRH. This step was repeated three times to establish a stable DA baseline. Next, cells were incubated with AMPH (1 or 10 μM) for 5 min followed by KRH removal, addition of fresh KRH and incubation for another 5 min. This procedure was repeated 4 times for a total of 20 min after AMPH incubation. The radioactivity of [³H]DA in each collection was counted. Data were calculated as a percent of baseline [³H]DA radioactivity and presented as Mean ± SEM. Atorvastatin treatment did not alter AMPH-induced DA efflux at both 1 μM (Fig. 4A) and 10 μM (Fig. 4B) concentrations (N=4/group).